RADCQ:OTC-Rite Aid Corporation (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 0.032

Change

+0.02 (+113.33)%

Market Cap

USD 0.01B

Volume

0.18M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-25 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
ALBHF Alibaba Health Information Tec..

+0.03 (+6.88%)

USD 7.22B
RADLY Raia Drogasil SA ADR

-0.64 (-13.47%)

USD 6.95B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.48B
SHPPF Shop Apotheke Europe N.V

N/A

USD 2.28B
ZRSEF Zur Rose Group AG

N/A

USD 1.12B
NVACF Nova Cannabis Inc

+0.02 (+1.85%)

USD 0.05B
NOTR Nowtransit Inc

N/A

USD 0.04B
RXMD Progressive Care Inc

N/A

USD 8.74M
HEWA Healthwarehouse.Com

N/A

USD 6.97M
FFLWF Fire & Flower Holdings Corp

N/A

USD 5.42M

ETFs Containing RADCQ

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -85.45% 7% C- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.45% 7% C- 3% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.01B 69% C- 39% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector